|
|
BY OUR PHARMA CORRESPONDENT
15 July, 2005: Aethlon Medical Inc is planning to start phase 2 studies on its new viral filtration device to treat HIV, hepatitis-C infections in India soon.
The US-based company involved in the development of viral filtration devices to treat HIV/AIDS, Hepatitis-C (HCV), will start its HIV and Hepatitis-C clinical trials in India next month. Qualtran LLC, a contract research organization (CRO) will manage the trials for Aethlon Medical Inc at the New Delhi based Apollo Hospital.
The Hemopurifier device is designed to reduce the presence of pathogenic viruses and toxins in the body. It converges the established scientific principals of affinity chromatography and haemodialysis as a means to augment the immune response of clearing viruses and toxins from the blood before cell and organ infection can occur.
It is estimated that, around 5.1 million individuals in India were infected with HIV in 2004, a ten-fold increase over the last decade. It is projected that the number of HIV-infected citizens in India could increase to 20-25 million by 2010.
Aethlon Medical is pioneering the development of viral filtration devices to treat drug and vaccine resistant pathogens. The market focus is the treatment of the Human Immunodeficiency Virus (HIV), hepatitis-C (HCV), and Biological Weapon candidates. Aethlon has an experienced management team, which receives support and guidance from globally recognized science advisors representing the infectious disease, biowarfare, and dialysis industries.
On March 4, 2004, Aethlon announced a cooperative agreement with the National Center for Biodefense (NCBD) at George Mason University. Under the agreement, Aethlon and the NCBD will collaborate to develop pathogen and toxin filtration devices designed to protect the lives of US Military personnel exposed to infectious agents as a result of biological warfare.
|
